Melanotan I

A synthetic α‑melanocyte‑stimulating hormone (α‑MSH) analogue, Melanotan I (afamelanotide) is designed to activate melanocortin receptors on skin pigment cells (melanocytes) Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide. By increasing eumelanin production, it boosts cutaneous pigmentation and reduces ultraviolet (UV)‑induced skin damage like sunburn Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+1. The strongest clinical evidence comes from erythropoietic protoporphyria (EPP), where real‑world studies show it markedly extends pain‑free light exposure and improves quality of life Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients+2. Early human trials also demonstrated photoprotection in fair‑skinned individuals, and a pediatric case report suggests possible use in children, though data remain limited Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+2.

Recent formulation research is exploring sustained‑release delivery platforms to prolong its effects Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery.

Melanotan I binds to the melanocortin 1 receptor (MC1R) on melanocytes, mimicking the natural hormone α‑MSH Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide+1. This binding turns on the cell’s pigment‑production machinery, favouring the synthesis of dark eumelanin over lighter pheomelanin Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide+1. The result is increased epidermal melanin density and a shift toward photoprotective pigmentation without the need for UV exposure Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients+1.

The photoprotection arises because extra eumelanin absorbs and scatters UV radiation, reducing the inflammatory skin response and sunburn‑cell formation seen after UV injury Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients+1. People with certain MC1R gene variants (often linked to fair skin and red hair) can still respond, but the effect may be less efficient Adjunctive use of <i>Polypodium leucotomos</i> extract in patients with erythropoietic protoporphyria: An exploratory study. The compound’s action is largely restricted to melanogenesis, unlike less selective melanocortin agonists that can affect appetite, libido, or the central nervous system Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

Clinical and observational studies have documented the following effects for Melanotan I/afamelanotide:

• Increased skin melanin density: Daily subcutaneous dosing in three 10‑day cycles (0.16 mg/kg) raised melanin levels, especially in lighter Fitzpatrick skin types Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+1. The pigmentation accumulates gradually over weeks.
• Reduced UV‑induced erythema and sunburn‑cell formation: Treated individuals showed less skin reddening and fewer damaged skin cells after controlled UV exposure, indicating biological photoprotection beyond simple tanning Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective.
• Improved light tolerance in EPP: In real‑world cohorts, afamelanotide increased median pain‑free light exposure time from 15 to 250 minutes and cut phototoxic reactions from 88% to 33% Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients. Quality‑of‑life scores rose substantially Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients+2.
• Uneven pigmentation: Because the peptide stimulates all melanocytes, pre‑existing moles, freckles, and scars can darken disproportionately Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+1. This requires regular skin checks.
• Mucosal darkening: Oral or genital mucosal pigmentation has been reported with melanocortin agonists, though most case reports involve Melanotan II Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report+1.

Published human studies used a regimen of 0.16 mg/kg given subcutaneously once daily for 10 consecutive days each month, repeated for three months Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery. This high‑dose approach was shown to increase skin melanin and reduce UV‑induced sunburn cells.

In contemporary research and community protocols, much lower flat doses are common, often starting at 0.25 mg per day and titrating upward based on pigmentation and tolerability. A typical loading phase runs for 10–20 days, followed by a maintenance phase of 0.25–0.5 mg two to three times per week. These lower doses are intended to produce visible tanning with fewer side effects, though they lack the rigorous safety data of the older trial.

All protocols require careful skin monitoring, as melanocortin stimulation can darken moles and make new lesions harder to spot. No oral or topical route is supported by the available evidence; subcutaneous injection is the primary method.

Melanotan I comes as a lyophilized powder that must be reconstituted before subcutaneous injection. Standard practice uses bacteriostatic water for multi‑dose vials to inhibit bacterial growth. The powder is gently swirled (not shaken) until the solution becomes clear; any cloudiness or visible particles indicate degradation and the vial should be discarded.

The peptide is sensitive to heat, light, and pH extremes, as confirmed by forced‑degradation studies on related α‑MSH analogues Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide. Lyophilized vials should be stored refrigerated (2–8 °C) and protected from light; frozen storage (−20 °C) extends shelf life. Once reconstituted, the solution should be kept at 2–8 °C and used within 28–30 days, sooner if any discoloration or precipitate appears. Minimize room‑temperature exposure during drawing and avoid repeated freeze‑thaw cycles.

The interactive reconstitution calculator below handles all dose‑by‑volume calculations for your specific vial size and desired dose. For qualitative handling: always work cleanly, disinfect the stopper, and discard any vial that shows signs of contamination.

There are few formal drug‑interaction studies with Melanotan I, but several practical concerns arise from its mechanism and real‑world use:

• UV exposure and tanning: Because the peptide reduces sunburn and increases pigmentation, users may tolerate longer sun exposure. This behavioral interaction can increase cumulative UV damage if caution is not maintained Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+1.
• Lesion monitoring: Darker skin makes it harder to visually track changes in moles. Baseline skin photography and routine dermatologic exams are advisable Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+1.
• Photosensitizing drugs: Medications that increase light sensitivity may still trigger reactions despite enhanced pigment. Monitor actual light tolerance when starting any new photosensitizer Discovery of MT-7117 (Dersimelagon Phosphoric Acid): A Novel, Potent, Selective, and Nonpeptidic Orally Available Melanocortin 1 Receptor Agonist.
• Hormonal agents: Melanogenesis can amplify hormonally driven hyperpigmentation (e.g., melasma). Caution is warranted in those with a history of uneven pigmentation Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective.
• Polypodium leucotomos: In a small EPP study, adding this oral fern extract to afamelanotide improved quality of life without added adverse events Adjunctive use of <i>Polypodium leucotomos</i> extract in patients with erythropoietic protoporphyria: An exploratory study. No other peptide‑peptide combinations are well studied.
• Storage and handling: Degradation products from heat, light, or improper reconstitution can alter potency and local tolerability; always protect the product Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

Combining Melanotan I with other peptides or supplements should be approached cautiously, as almost no controlled combination studies exist.

• With Polypodium leucotomos: An exploratory study in EPP patients already on afamelanotide found that adding oral Polypodium leucotomos extract provided modest additional quality‑of‑life improvement without extra side effects Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients. This is the most evidence‑backed stack.
• With other melanocortin agonists (e.g., Melanotan II): Avoid stacking. Both compounds act on MC1R and can unpredictably amplify pigmentation, nausea, or systemic effects (practitioner consensus).
• With appetite‑modulating peptides (GLP‑1 agonists, etc.): Melanocortin signalling influences feeding, and there is theoretical overlap. If used together, monitor for unexpected nausea, appetite changes, or energy level shifts.
• With “tanning peptides” from unregulated sources: These often contain Melanotan II or unknown mixtures. Purity and dosing are unreliable, making stacking especially risky Discovery of MT-7117 (Dersimelagon Phosphoric Acid): A Novel, Potent, Selective, and Nonpeptidic Orally Available Melanocortin 1 Receptor Agonist+1.

In general, simplify your protocol and add only one new compound at a time to assess individual effects. Skin monitoring remains essential whenever pigmentation is being forced.

Afamelanotide (the therapeutic formulation of Melanotan I) is approved in multiple regions for erythropoietic protoporphyria and is marketed as a 16 mg implant (SCENESSE) Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide+2. The U.S. FDA has approved it for this indication. However, any product sold as “Melanotan I” outside of legitimate pharmacy channels is an unlicensed, unregulated substance.

Regulatory agencies such as the UK’s MHRA have explicitly advised consumers not to use melanotan products because they are sold illegally and lack quality and safety oversight German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP)+1. These warnings extend to all melanotan analogues purchased online, often labeled “research chemicals only” An in-depth case examination of an exotic dancer's experience of melanotan+1.

In sports, no WADA or USADA prohibitions specific to Melanotan I appear in the provided corpus. Nevertheless, athletes are urged to verify status on the current WADA Prohibited List, as many melanocortin agonists are obtained from unreliable sources that may contain banned contaminants or mislabeled ingredients.

Common effects

• Injection‑site reactions (redness, swelling) are typical for subcutaneous peptides.
• Generalized skin darkening is the intended effect; it can be cosmetically excessive in fair‑skinned individuals Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective.

Uncommon effects

• Uneven darkening of moles, freckles, and scars is pharmacologically predictable Clinical potential of Melanotan^® (NDP‐α‐MSH) in skin protection – current status and future perspective+1.
• Mucosal pigmentation (inside the mouth) has been seen with melanocortin agonists, though more often with Melanotan II Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.

Rare / theoretical risks

• Case reports link melanotan use (predominantly Melanotan II) to eruptive nevi and melanoma in situ. While a direct causal link is not proven, the peptide’s stimulation of melanocytes warrants vigilance Melanoma In-Situ Associated with Melanotan Ii Use+2.
• Degradation products from mishandled peptide may cause unpredictable local or systemic reactions, as afamelanotide is chemically unstable under heat, light, and pH stress Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

Contraindications

• Avoid in anyone with active melanoma or suspicious pigmented lesions until cleared by a dermatologist.
• Use extreme caution in those with a personal or strong family history of melanoma, dysplastic nevus syndrome, or rapid mole changes.
• Not recommended for pregnant or breastfeeding individuals; no safety data exist.

Monitoring

• Baseline full‑body skin exam with photographic documentation of atypical nevi.
• Monthly self‑checks and dermatologic exams every 3–6 months while using the peptide.
• Stop and consult a doctor immediately if any mole becomes asymmetric, darkens quickly, bleeds, or changes shape.